

The epigenetic landscape of T cell exhaustion

Science

354, 1165-1169

DOI: [10.1126/science.aae0491](https://doi.org/10.1126/science.aae0491)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Can T cells be too exhausted to fight back?. Science, 2016, 354, 1104-1105.	6.0	12
2	SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity, 2017, 46, 51-64.	6.6	122
3	Satb1: Restraining PD1 and T Cell Exhaustion. Immunity, 2017, 46, 3-5.	6.6	19
4	The chronicles of T-cell exhaustion. Nature, 2017, 543, 190-191.	13.7	24
5	The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. Molecular Therapy, 2017, 25, 880-891.	3.7	50
6	Exhaustion-associated regulatory regions in CD8 ⁺ tumor-infiltrating T cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2776-E2785.	3.3	242
7	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood, 2017, 129, 2186-2197.	0.6	156
8	The Principles of Engineering Immune Cells to Treat Cancer. Cell, 2017, 168, 724-740.	13.5	844
9	Cutting Edge: Chromatin Accessibility Programs CD8 T Cell Memory. Journal of Immunology, 2017, 198, 2238-2243.	0.4	68
10	Metabolic and Epigenetic Coordination of T Cell and Macrophage Immunity. Immunity, 2017, 46, 714-729.	6.6	234
11	Epigenetic Remodeling in Exhausted T Cells. Transplantation, 2017, 101, 894-895.	0.5	3
12	Is autoimmunity the Achilles' heel of cancer immunotherapy?. Nature Medicine, 2017, 23, 540-547.	15.2	367
13	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Reports, 2017, 19, 875-889.	2.9	78
14	Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell, 2017, 169, 1342-1356.e16.	13.5	1,540
15	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. Journal of Leukocyte Biology, 2017, 102, 601-615.	1.5	39
16	Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature, 2017, 545, 452-456.	13.7	643
17	Industry 'road tests' new wave of immune checkpoints. Nature Biotechnology, 2017, 35, 487-488.	9.4	11
18	Epigenetic modulation in cancer immunotherapy. Current Opinion in Pharmacology, 2017, 35, 48-56.	1.7	50

#	ARTICLE	IF	CITATIONS
19	Immune engineering: From systems immunology to engineering immunity. <i>Current Opinion in Biomedical Engineering</i> , 2017, 1, 54-62.	1.8	7
20	Obstacles Posed by the Tumor Microenvironment to T _H 1 Cell Activity: A Case for Synergistic Therapies. <i>Cancer Cell</i> , 2017, 31, 311-325.	7.7	502
21	Functional interrogation of non-coding DNA through CRISPR genome editing. <i>Methods</i> , 2017, 121-122, 118-129.	1.9	28
22	Successful and Maladaptive T Cell Aging. <i>Immunity</i> , 2017, 46, 364-378.	6.6	250
23	High-Throughput Approaches to Pinpoint Function within the Noncoding Genome. <i>Molecular Cell</i> , 2017, 68, 44-59.	4.5	54
24	Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1323-1332.	1.5	35
25	Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells. <i>Human Gene Therapy</i> , 2017, 28, 1047-1060.	1.4	35
26	Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945.	1.3	34
27	Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. <i>Cell Reports</i> , 2017, 20, 1017-1028.	2.9	156
28	Stochastics of Cellular Differentiation Explained by Epigenetics: The Case of T _H 1 Cell Differentiation and Functional Plasticity. <i>Scandinavian Journal of Immunology</i> , 2017, 86, 184-195.	1.3	8
29	Modulation of antitumor immunity with histone deacetylase inhibitors. <i>Immunotherapy</i> , 2017, 9, 1359-1372.	1.0	37
30	Challenges and recommendations for epigenomics in precision health. <i>Nature Biotechnology</i> , 2017, 35, 1128-1132.	9.4	19
31	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology</i> , The, 2017, 18, e731-e741.	5.1	568
32	32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) Tj ETQq1 1 0.784314,rgBT /O	2.3	23
33	Precision Medicine, CRISPR, and Genome Engineering. <i>Advances in Experimental Medicine and Biology</i> , 2017, , , .	0.8	2
34	Target Discovery for Precision Medicine Using High-Throughput Genome Engineering. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1016, 123-145.	0.8	6
35	Molecular Dissection of CD8 + T-Cell Dysfunction. <i>Trends in Immunology</i> , 2017, 38, 567-576.	2.9	51
36	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225

#	ARTICLE	IF	CITATIONS
37	Epigenetic Strategies to Boost Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1108.	1.8	29
38	NK Cell Exhaustion. <i>Frontiers in Immunology</i> , 2017, 8, 760.	2.2	221
39	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1215.	2.2	80
40	The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1718.	2.2	36
41	Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. <i>Pathogens and Immunity</i> , 2017, 2, 102.	1.4	11
42	CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. <i>OncolImmunology</i> , 2018, 7, e1440169.	2.1	219
43	Metabolites, genome organization, and cellular differentiation gene programs. <i>Current Opinion in Immunology</i> , 2018, 51, 62-67.	2.4	7
44	CRISPR-based methods for high-throughput annotation of regulatory DNA. <i>Current Opinion in Biotechnology</i> , 2018, 52, 32-41.	3.3	13
45	The (gradual) rise of memory inflation. <i>Immunological Reviews</i> , 2018, 283, 99-112.	2.8	70
46	The function and dysfunction of memory CD8 ⁺ T cells in tumor immunity. <i>Immunological Reviews</i> , 2018, 283, 194-212.	2.8	121
47	Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells. <i>Immunity</i> , 2018, 48, 773-786.e5.	6.6	150
48	Enhancer talk. <i>Epigenomics</i> , 2018, 10, 483-498.	1.0	32
49	T Cell Dysfunction in Cancer. <i>Cancer Cell</i> , 2018, 33, 547-562.	7.7	787
50	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
51	Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. <i>Current Opinion in Virology</i> , 2018, 30, 1-8.	2.6	36
52	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018, 69, 301-318.	5.0	432
53	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
54	Epigenetic control of CD8+ T cell differentiation. <i>Nature Reviews Immunology</i> , 2018, 18, 340-356.	10.6	334

#	ARTICLE	IF	CITATIONS
55	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. <i>Annals of Oncology</i> , 2018, 29, 812-824.	0.6	73
56	Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 192-202.	3.7	75
57	MAIT cells and viruses. <i>Immunology and Cell Biology</i> , 2018, 96, 630-641.	1.0	90
58	Disease tolerance: concept and mechanisms. <i>Current Opinion in Immunology</i> , 2018, 50, 88-93.	2.4	108
59	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	1.6	24
60	Connections Between Metabolism and Epigenetics in Programming Cellular Differentiation. <i>Annual Review of Immunology</i> , 2018, 36, 221-246.	9.5	93
61	Mechanisms of resistance to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2018, 118, 9-16.	2.9	944
62	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
63	Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. <i>Journal of Immunology</i> , 2018, 200, 450-458.	0.4	78
64	Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
65	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	1.5	79
66	Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery. <i>Oncotarget</i> , 2018, 7, e1448330.	2.1	24
67	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.	6.6	416
68	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274
69	Tumor infiltrating lymphocytes in early breast cancer. <i>Breast</i> , 2018, 37, 207-214.	0.9	108
70	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	2.4	351
71	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	10.6	1,210
72	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	10.6	407

#	ARTICLE	IF	CITATIONS
73	PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?. <i>Onc Immunology</i> , 2018, 7, e1364828.	2.1	243
74	Emerging trends in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2018, 417, 35-46.	3.2	77
75	Metabolic Control of CD8+ T Cell Fate Decisions and Antitumor Immunity. <i>Trends in Molecular Medicine</i> , 2018, 24, 30-48.	3.5	158
76	Phase I Study of Chimeric Antigen Receptorâ€“Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1277-1286.	3.2	159
77	CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. <i>Blood</i> , 2018, 131, 311-322.	0.6	159
78	CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cellâ€“Relevant Genes. <i>Cancer Immunology Research</i> , 2018, 6, 69-78.	1.6	34
79	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. <i>JCI Insight</i> , 2018, 3, .	2.3	49
80	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity. <i>Frontiers in Pediatrics</i> , 2018, 6, 373.	0.9	53
81	T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. <i>Frontiers in Immunology</i> , 2018, 9, 2569.	2.2	241
82	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC). , 2018, , 341-355.		2
83	The antitumor effects of entinostat in ovarian cancer require adaptive immunity. <i>Cancer</i> , 2018, 124, 4657-4666.	2.0	22
85	Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. <i>Cell</i> , 2018, 175, 1958-1971.e15.	13.5	378
86	Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. <i>Nature Medicine</i> , 2018, 24, 978-985.	15.2	1,044
87	High Levels of Eomes Promote Exhaustion of Anti-tumor CD8+ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2981.	2.2	137
88	Interleukin 2 modulates thymic-derived regulatory T cell epigenetic landscape. <i>Nature Communications</i> , 2018, 9, 5368.	5.8	26
89	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2018, 13, 611-619.	1.7	3
90	Limited Phenotypic and Functional Plasticity of Influenza Virusâ€“Specific Memory CD8+T Cells during Activation in an Alternative Cytokine Environment. <i>Journal of Immunology</i> , 2018, 201, 3282-3293.	0.4	2
91	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	3.6	36

#	ARTICLE	IF	CITATIONS
92	Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 ⁺ T cell dysfunction and maintain memory phenotype. <i>Science Immunology</i> , 2018, 3, .	5.6	133
93	Nobel goes to immune checkpoint—Innovative cancer treatment by immunotherapy. <i>Science China Life Sciences</i> , 2018, 61, 1445-1450.	2.3	3
94	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	13.5	1,260
95	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. <i>Molecular Therapy</i> , 2018, 26, 2553-2566.	3.7	20
96	Epigenetic mechanisms regulating T-cell responses. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 728-743.	1.5	100
97	Epigenetic programming of T cells impacts immune reconstitution in hematopoietic stem cell transplant recipients. <i>Blood Advances</i> , 2018, 2, 656-668.	2.5	8
98	Transcription Factor IRF8 Orchestrates the Adaptive Natural Killer Cell Response. <i>Immunity</i> , 2018, 48, 1172-1182.e6.	6.6	100
99	Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 ⁺ T Cells. <i>Immunity</i> , 2018, 48, 1029-1045.e5.	6.6	250
100	Strength in diversity: Phenotypic, functional, and molecular heterogeneity within the memory B cell repertoire. <i>Immunological Reviews</i> , 2018, 284, 67-78.	2.8	29
101	Epigenetics of T cell aging. <i>Journal of Leukocyte Biology</i> , 2018, 104, 691-699.	1.5	46
102	CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. <i>Cancer Research</i> , 2018, 78, 4692-4703.	0.4	140
103	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. <i>Mammalian Genome</i> , 2018, 29, 866-878.	1.0	10
104	PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of <i>Toxoplasma gondii</i> . <i>Infection and Immunity</i> , 2018, 86, .	1.0	14
105	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1786.	2.2	29
106	Epigenetic control of innate and adaptive immune memory. <i>Nature Immunology</i> , 2018, 19, 963-972.	7.0	217
107	Disrupting the Code: Epigenetic Dysregulation of Lymphocyte Function during Infectious Disease and Lymphoma Development. <i>Journal of Immunology</i> , 2018, 201, 1109-1118.	0.4	17
108	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. <i>Nature Medicine</i> , 2018, 24, 1143-1150.	15.2	212
109	Hepatitis B Virus-Specific CD8 ⁺ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment. <i>Frontiers in Immunology</i> , 2018, 9, 219.	2.2	48

#	ARTICLE	IF	CITATIONS
110	Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes. <i>Frontiers in Immunology</i> , 2018, 9, 339.	2.2	133
111	H3K4me3 mediates the NF- κ B p50 homodimer binding to the <i>pdc1</i> promoter to activate PD-1 transcription in T cells. <i>Oncotmmunology</i> , 2018, 7, e1483302.	2.1	15
112	Regulation of Memory CD8+ T Cell Differentiation by MicroRNAs. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 2187-2198.	1.1	18
113	Sirtuin1 Targeting Reverses Innate and Adaptive Immune Tolerance in Septic Mice. <i>Journal of Immunology Research</i> , 2018, 2018, 1-13.	0.9	16
114	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-13.	3.2	152
115	Epigenetic mechanisms of tumor resistance to immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4163-4176.	2.4	27
116	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
117	Ctrl-Alt-inDel: genome editing to reprogram a cell in the clinic. <i>Current Opinion in Genetics and Development</i> , 2018, 52, 48-56.	1.5	11
118	Decoding the noncoding genome via large-scale CRISPR screens. <i>Current Opinion in Genetics and Development</i> , 2018, 52, 70-76.	1.5	20
119	Induction and transcriptional regulation of the co-inhibitory gene module in T cells. <i>Nature</i> , 2018, 558, 454-459.	13.7	336
120	The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 31-43.	3.6	79
121	Long-term reprogramming of the innate immune system. <i>Journal of Leukocyte Biology</i> , 2019, 105, 329-338.	1.5	120
122	Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. <i>Cell Reports</i> , 2019, 28, 2140-2155.e6.	2.9	64
123	Detect accessible chromatin using ATAC-sequencing, from principle to applications. <i>Hereditas</i> , 2019, 156, 29.	0.5	49
124	Beyond the Exome: The Non-coding Genome and Enhancers in Neurodevelopmental Disorders and Malformations of Cortical Development. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 352.	1.8	53
125	Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression. <i>Trends in Cell Biology</i> , 2019, 29, 777-790.	3.6	48
126	Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. <i>Nature Biotechnology</i> , 2019, 37, 925-936.	9.4	622
127	The transcription factor TCF-1 enforces commitment to the innate lymphoid cell lineage. <i>Nature Immunology</i> , 2019, 20, 1150-1160.	7.0	81

#	ARTICLE	IF	CITATIONS
128	The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer. <i>Clinical Oncology</i> , 2019, 31, 834-843.	0.6	48
130	HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules. <i>Scientific Reports</i> , 2019, 9, 10624.	1.6	27
131	T Cell Dysfunction in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1719.	2.2	219
132	Hepatitis C Virus as a Unique Human Model Disease to Define Differences in the Transcriptional Landscape of T Cells in Acute versus Chronic Infection. <i>Viruses</i> , 2019, 11, 683.	1.5	5
133	CD8+ T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 1896.	2.2	52
134	Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing. <i>Cancer Immunology Research</i> , 2019, 7, 1040-1046.	1.6	57
135	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. <i>Nature</i> , 2019, 571, 211-218.	13.7	934
136	The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 207.	1.8	194
137	New Clones on the Block. <i>Immunity</i> , 2019, 51, 606-608.	6.6	4
138	Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2240.	2.2	31
139	TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 ⁺ T Cell-Fate Decision. <i>Immunity</i> , 2019, 51, 840-855.e5.	6.6	409
140	Common gamma chain cytokines and CD8 T cells in cancer. <i>Seminars in Immunology</i> , 2019, 42, 101307.	2.7	25
141	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. <i>Drug Resistance Updates</i> , 2019, 47, 100646.	6.5	81
142	Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances anti-glioma therapeutic function. <i>Journal of Neuro-Oncology</i> , 2019, 145, 429-439.	1.4	33
143	Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1926.	2.2	41
144	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4320.	1.8	43
145	Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. <i>Nature Communications</i> , 2019, 10, 4109.	5.8	72
146	Systematically understanding the immunity leading to CRPC progression. <i>PLoS Computational Biology</i> , 2019, 15, e1007344.	1.5	23

#	ARTICLE	IF	CITATIONS
147	The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality. <i>Immunity</i> , 2019, 51, 491-507.e7.	6.6	148
148	Defining "T cell exhaustion". <i>Nature Reviews Immunology</i> , 2019, 19, 665-674.	10.6	879
149	Regulatory T cells in cancer immunosuppression " implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	12.5	872
150	CRISPR-Based Tools in Immunity. <i>Annual Review of Immunology</i> , 2019, 37, 571-597.	9.5	38
151	Is There a Positive Side to T Cell Exhaustion?. <i>Frontiers in Immunology</i> , 2019, 10, 111.	2.2	32
152	Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. <i>Cancer Research</i> , 2019, 79, 1493-1506.	0.4	118
153	CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. <i>Annual Review of Immunology</i> , 2019, 37, 457-495.	9.5	1,143
154	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019, 19, 151-161.	12.8	345
155	Development of circulating CD4 ⁺ T cell memory. <i>Immunology and Cell Biology</i> , 2019, 97, 617-624.	1.0	12
156	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	2.2	20
157	Adaptation and memory in immune responses. <i>Nature Immunology</i> , 2019, 20, 783-792.	7.0	109
158	TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 731-741.	1.8	193
159	Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. <i>Current Opinion in Immunology</i> , 2019, 58, 98-103.	2.4	83
160	The next generation of CRISPR-Cas technologies and applications. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 490-507.	16.1	957
161	TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 ⁺ T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 12410-12415.	3.3	481
162	Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1034.	2.2	39
163	HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2754.	1.8	43
164	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 7680.	1.6	36

#	ARTICLE	IF	CITATIONS
165	Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models. <i>Cancer Immunology Research</i> , 2019, 7, 963-976.	1.6	36
166	Curing HIV by “kick and kill”™: from theory to practice?. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 383-386.	2.0	3
167	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
168	Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8 ⁺ T Cells. <i>Immunity</i> , 2019, 50, 1202-1217.e7.	6.6	51
169	Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?. <i>Journal of Oncology</i> , 2019, 2019, 1-18.	0.6	5
170	Addition of Low-Dose Decitabine to Anti-“PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1479-1489.	0.8	135
171	CD8+ T cell exhaustion. <i>Seminars in Immunopathology</i> , 2019, 41, 327-337.	2.8	169
172	Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. <i>PLoS ONE</i> , 2019, 14, e0212347.	1.1	4
173	Towards multiscale modeling of the CD8 ⁺ T cell response to viral infections. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2019, 11, e1446.	6.6	16
174	YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. <i>Drug Resistance Updates</i> , 2019, 43, 10-28.	6.5	81
175	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 491.	2.2	23
176	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
177	Therapeutic Cancer Vaccines“T Cell Responses and Epigenetic Modulation. <i>Frontiers in Immunology</i> , 2018, 9, 3109.	2.2	26
178	The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8 T Cells During Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2019, 10, 169.	2.2	66
179	Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. <i>Nature</i> , 2019, 567, 525-529.	13.7	311
180	NR4A transcription factors limit CAR T cell function in solid tumours. <i>Nature</i> , 2019, 567, 530-534.	13.7	519
181	Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. <i>Nature Immunology</i> , 2019, 20, 326-336.	7.0	1,148
182	CD4 ⁺ T help promotes influenza virus-specific CD8 ⁺ T cell memory by limiting metabolic dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4481-4488.	3.3	42

#	ARTICLE	IF	CITATIONS
183	Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus. <i>Viruses</i> , 2019, 11, 156.	1.5	32
184	<p>DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10903-10916.	1.0	53
185	Metabolic Control of Epigenetics and Its Role in CD8+ T Cell Differentiation and Function. <i>Frontiers in Immunology</i> , 2019, 10, 2718.	2.2	36
186	Liver-Mediated Adaptive Immune Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 2525.	2.2	125
187	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. <i>Clinical Epigenetics</i> , 2019, 11, 161.	1.8	49
188	c-Jun overexpression in CAR T cells induces exhaustion resistance. <i>Nature</i> , 2019, 576, 293-300.	13.7	480
189	Tâ€cell exhaustion in HIV infection. <i>Immunological Reviews</i> , 2019, 292, 149-163.	2.8	217
190	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	1.2	54
191	PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. <i>Nature Immunology</i> , 2019, 20, 1335-1347.	7.0	142
192	Fibroblastic reticular cells enhance T cell metabolism and survival via epigenetic remodeling. <i>Nature Immunology</i> , 2019, 20, 1668-1680.	7.0	53
193	Enforcing the checkpoints. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 213-218.	1.2	25
194	Epigenetic regulation of the hypoxic response. <i>Current Opinion in Physiology</i> , 2019, 7, 1-8.	0.9	5
195	Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. <i>Gut</i> , 2019, 68, 893-904.	6.1	102
196	Multilayer regulation of CD4 T cell subset differentiation in the era of single cell genomics. <i>Advances in Immunology</i> , 2019, 141, 1-31.	1.1	13
197	Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1âˆCD8+ Tumor-Infiltrating T Cells. <i>Immunity</i> , 2019, 50, 181-194.e6.	6.6	424
198	T cell toxicity of HIV latency reversing agents. <i>Pharmacological Research</i> , 2019, 139, 524-534.	3.1	35
199	T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. <i>Journal of Medical Genetics</i> , 2019, 56, 22-28.	1.5	12
200	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093

#	ARTICLE	IF	CITATIONS
201	The pathogenesis of thyroid autoimmune diseases: New T lymphocytes “ Cytokines circuits beyond the Th1~Th2 paradigm. <i>Journal of Cellular Physiology</i> , 2019, 234, 2204-2216.	2.0	83
202	Cytokine-Mediated Regulation of CD8 T-Cell Responses During Acute and Chronic Viral Infection. <i>Cold Spring Harbor Perspectives in Biology</i> , 2019, 11, a028464.	2.3	38
203	CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. <i>Briefings in Functional Genomics</i> , 2019, 18, 99-106.	1.3	77
204	Genomic and epigenomic perspectives of T-cell exhaustion in cancer. <i>Briefings in Functional Genomics</i> , 2019, 18, 113-118.	1.3	6
205	Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 73-103.	1.8	15
206	The emerging role of epigenetic therapeutics in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 75-90.	12.5	260
207	Precursor exhausted T cells: key to successful immunotherapy?. <i>Nature Reviews Immunology</i> , 2020, 20, 128-136.	10.6	253
208	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. <i>Seminars in Cancer Biology</i> , 2020, 65, 13-27.	4.3	170
209	PD-1 Expression during Acute Infection Is Repressed through an LSD1~Blimp-1 Axis. <i>Journal of Immunology</i> , 2020, 204, 449-458.	0.4	24
210	Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 27-35.	4.8	168
211	Immuno-Oncology. <i>Methods in Pharmacology and Toxicology</i> , 2020, , .	0.1	4
212	Prevention of CAR-T-cell dysfunction. <i>Nature Biomedical Engineering</i> , 2020, 4, 16-17.	11.6	2
213	Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. <i>Aids</i> , 2020, 34, 197-202.	1.0	6
214	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3441-3452.	2.4	22
215	An Introduction to CAR Immunotherapy. , 2020, , 1-11.		1
216	Memory T cell, exhaustion, and tumor immunity. <i>Immunological Medicine</i> , 2020, 43, 1-9.	1.4	118
217	Stem, Effector, and Hybrid States of Memory CD8+ T Cells. <i>Trends in Immunology</i> , 2020, 41, 17-28.	2.9	65
218	Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications. <i>Trends in Immunology</i> , 2020, 41, 29-45.	2.9	46

#	ARTICLE	IF	CITATIONS
219	Landscape of Exhausted Virus-Specific CD8 ⁺ T Cells in Chronic LCMV Infection. <i>Cell Reports</i> , 2020, 32, 108078.	2.9	45
220	Role of Nurr1 in Carcinogenesis and Tumor Immunology: A State of the Art Review. <i>Cancers</i> , 2020, 12, 3044.	1.7	8
221	Cellular and Molecular Mechanisms of CD8 ⁺ T Cell Differentiation, Dysfunction and Exhaustion. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7357.	1.8	43
222	Two subsets of stem-like CD8 ⁺ memory T cell progenitors with distinct fate commitments in humans. <i>Nature Immunology</i> , 2020, 21, 1552-1562.	7.0	167
223	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	1.3	47
224	Disturbed mitochondrial dynamics in CD8 ⁺ TILs reinforce T cell exhaustion. <i>Nature Immunology</i> , 2020, 21, 1540-1551.	7.0	252
225	Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. <i>Nature Immunology</i> , 2020, 21, 1022-1033.	7.0	227
226	Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 1010-1021.	7.0	85
227	T Cell-Intrinsic IRF5 Regulates T Cell Signaling, Migration, and Differentiation and Promotes Intestinal Inflammation. <i>Cell Reports</i> , 2020, 31, 107820.	2.9	25
228	Analysis of single-cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e133.	1.7	17
229	An Integrated Epigenomic and Transcriptomic Map of Mouse and Human T Cell Development. <i>Immunity</i> , 2020, 53, 1182-1201.e8.	6.6	49
230	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18
231	Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. <i>Nature Communications</i> , 2020, 11, 6268.	5.8	206
232	ATAC-seq with unique molecular identifiers improves quantification and footprinting. <i>Communications Biology</i> , 2020, 3, 675.	2.0	21
233	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , 2020, 26, 1468-1479.	15.2	87
234	Unraveling the Complexity of the Cancer Microenvironment With Multidimensional Genomic and Cytometric Technologies. <i>Frontiers in Oncology</i> , 2020, 10, 1254.	1.3	45
235	Premature aging of circulating T cells predicts all-cause mortality in hemodialysis patients. <i>BMC Nephrology</i> , 2020, 21, 271.	0.8	17
236	The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. <i>Future Medicinal Chemistry</i> , 2020, 12, 1415-1430.	1.1	16

#	ARTICLE	IF	CITATIONS
237	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2020, 10, 1061.	1.8	59
238	Adaptive Immune Response against Hepatitis C Virus. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5644.	1.8	18
239	Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell. <i>World Journal of Surgical Oncology</i> , 2020, 18, 196.	0.8	7
240	Reversal of T Cell Exhaustion in Chronic HCV Infection. <i>Viruses</i> , 2020, 12, 799.	1.5	14
241	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. <i>Genome Biology</i> , 2020, 21, 263.	3.8	15
242	EZH2 as a Regulator of CD8+ T Cell Fate and Function. <i>Frontiers in Immunology</i> , 2020, 11, 593203.	2.2	26
244	Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion. <i>Frontiers in Immunology</i> , 2020, 11, 592569.	2.2	25
245	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. <i>Nature</i> , 2020, 585, 277-282.	13.7	280
246	Metabolic and epigenetic regulation of T-cell exhaustion. <i>Nature Metabolism</i> , 2020, 2, 1001-1012.	5.1	167
247	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	8
248	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23684-23694.	3.3	32
249	Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. <i>Immunity</i> , 2020, 53, 658-671.e6.	6.6	98
250	The Transcription Factor TCF1 in T Cell Differentiation and Aging. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6497.	1.8	49
251	Early precursor T cells establish and propagate T cell exhaustion in chronic infection. <i>Nature Immunology</i> , 2020, 21, 1256-1266.	7.0	160
252	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. <i>Respiration</i> , 2020, 99, 903-929.	1.2	18
253	T cell factor 1: A master regulator of the T cell response in disease. <i>Science Immunology</i> , 2020, 5, .	5.6	85
254	Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	10
255	Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion. <i>Oncolmmunology</i> , 2020, 9, 1747349.	2.1	11

#	ARTICLE	IF	CITATIONS
256	T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?. <i>Leukemia</i> , 2020, 34, 2012-2024.	3.3	70
257	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e275-e291.	1.8	32
258	Emerging technologies for systems vaccinology – multi-omics integration and single-cell (epi)genomic profiling. <i>Current Opinion in Immunology</i> , 2020, 65, 57-64.	2.4	23
259	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. <i>Biomarker Research</i> , 2020, 8, 19.	2.8	42
260	Epigenetics mechanisms driving immune memory cell differentiation and function. , 2020, , 117-137.		1
261	Systems immunology meets epigenetics. , 2020, , 239-252.		0
262	Characterization of functional transposable element enhancers in acute myeloid leukemia. <i>Science China Life Sciences</i> , 2020, 63, 675-687.	2.3	7
263	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. <i>Frontiers in Immunology</i> , 2020, 11, 372.	2.2	20
264	Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2020, 11, 401.	2.2	39
265	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 490.	2.2	38
266	Checkpoint inhibitor blockade and epigenetic reprogrammability in CD8+ T-cell activation and exhaustion. , 2020, 8, 251513552090423.	1.4	2
267	T Cell Dysfunction and Exhaustion in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 17.	1.8	226
268	Synthetic immunity by remote control. <i>Theranostics</i> , 2020, 10, 3652-3667.	4.6	17
269	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. <i>Cell</i> , 2020, 180, 895-914.e27.	13.5	127
270	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. <i>Frontiers in Immunology</i> , 2020, 11, 1350.	2.2	13
271	Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR) Tj ETQq1_1_0.784314 rgBT /Dv	2.1	34
272	Toward Systems Biomarkers of Response to Immune Checkpoint Blockers. <i>Frontiers in Oncology</i> , 2020, 10, 1027.	1.3	16
273	Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promoter methylation. <i>PLoS Pathogens</i> , 2020, 16, e1008555.	2.1	36

#	ARTICLE	IF	CITATIONS
274	Chromatin Priming Renders T Cell Tolerance-Associated Genes Sensitive to Activation below the Signaling Threshold for Immune Response Genes. <i>Cell Reports</i> , 2020, 31, 107748.	2.9	21
275	Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 665-675.	2.9	42
276	Cancer Epigenetics, Tumor Immunity, and Immunotherapy. <i>Trends in Cancer</i> , 2020, 6, 580-592.	3.8	166
277	Use of Mass Cytometry to Profile Human T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2019, 10, 3039.	2.2	37
278	Epigenetics of T cell fate decision. <i>Current Opinion in Immunology</i> , 2020, 63, 43-50.	2.4	21
279	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. <i>Cell Research</i> , 2020, 30, 285-299.	5.7	129
280	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. <i>Cancer Discovery</i> , 2020, 10, 552-567.	7.7	184
281	Dynamic Post-Transcriptional Events Governing CD8+ T Cell Homeostasis and Effector Function. <i>Trends in Immunology</i> , 2020, 41, 240-254.	2.9	39
282	Cancer immunotherapy: Pros, cons and beyond. <i>Biomedicine and Pharmacotherapy</i> , 2020, 124, 109821.	2.5	337
284	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53
285	Unravelling the heterogeneity and dynamic relationships of tumor-infiltrating T cells by single-cell RNA sequencing analysis. <i>Journal of Leukocyte Biology</i> , 2020, 107, 917-932.	1.5	21
286	The Emerging Landscape of Immune Cell Therapies. <i>Cell</i> , 2020, 181, 46-62.	13.5	247
287	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy. <i>EBioMedicine</i> , 2020, 54, 102727.	2.7	42
288	HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2020, 94, .	1.5	28
289	Calcium phosphate nanoneedle based gene delivery system for cancer genetic immunotherapy. <i>Biomaterials</i> , 2020, 250, 120072.	5.7	27
290	Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response. <i>BMC Immunology</i> , 2020, 21, 22.	0.9	14
291	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. <i>Clinical Cancer Research</i> , 2020, 26, 2087-2095.	3.2	35
292	CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 912-925.	1.6	53

#	ARTICLE	IF	CITATIONS
293	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
294	Ectopic Tcf1 expression instills a stem-like program in exhausted CD8+ T cells to enhance viral and tumor immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1262-1277.	4.8	49
295	Targeting metabolism to reverse T cell exhaustion in chronic viral infections. <i>Immunology</i> , 2021, 162, 135-144.	2.0	23
296	Metabolic regulation of the HBV-specific T cell function. <i>Antiviral Research</i> , 2021, 185, 104989.	1.9	9
297	Understanding the tumor microenvironment for effective immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1474-1498.	5.0	130
298	Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 111-128.	0.9	5
299	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	2.0	22
300	Origin and fine-tuning of effector CD8 T cell subpopulations in chronic infection. <i>Current Opinion in Virology</i> , 2021, 46, 27-35.	2.6	4
301	Role, function and regulation of the thymocyte selection-associated high mobility group box protein in CD8+ T cell exhaustion. <i>Immunology Letters</i> , 2021, 229, 1-7.	1.1	9
302	SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2021, 206, 193-205.	0.4	40
303	Notch signaling defects in NK cells in patients with cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 981-988.	2.0	4
304	Reinvigorating exhausted CD8 ⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
305	The DNA methylation landscape of PD-1 (<i>PDCD1</i>) and adjacent lncRNA <i>AC131097.3</i> in head and neck squamous cell carcinoma. <i>Epigenomics</i> , 2021, 13, 113-127.	1.0	9
306	Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 215-229.	12.5	486
308	CRISPR technologies for precise epigenome editing. <i>Nature Cell Biology</i> , 2021, 23, 11-22.	4.6	248
309	The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. <i>Cancers</i> , 2021, 13, 134.	1.7	67
310	Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. <i>Cells</i> , 2021, 10, 56.	1.8	14
311	Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. <i>Nature Immunology</i> , 2021, 22, 205-215.	7.0	358

#	ARTICLE	IF	CITATIONS
312	Ontogeny and heterogeneity of innate lymphoid cells and the noncoding genome. <i>Immunological Reviews</i> , 2021, 300, 152-166.	2.8	8
313	BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells. <i>Nature Immunology</i> , 2021, 22, 370-380.	7.0	75
314	Exhausted T cells in systemic lupus erythematosus patients in long-standing remission. <i>Clinical and Experimental Immunology</i> , 2021, 204, 285-295.	1.1	14
315	Functionally Competent, PD-1+ CD8+ Trm Cells Populate the Brain Following Local Antigen Encounter. <i>Frontiers in Immunology</i> , 2020, 11, 595707.	2.2	6
316	A Regenerative Perspective on Successful and Failed T-Cell Immunity. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037937.	2.3	2
317	Combination immunotherapy strategies for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 151, 375-391.	1.4	38
318	T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	35
319	Persistence of self-reactive CD8+ T cells in the CNS requires TOX-dependent chromatin remodeling. <i>Nature Communications</i> , 2021, 12, 1009.	5.8	19
320	Epigenetic Mechanisms beyond Tumour-Stroma Crosstalk. <i>Cancers</i> , 2021, 13, 914.	1.7	10
321	Improved Functionality of Exhausted Intrahepatic CXCR5+ CD8+ T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation. <i>Frontiers in Immunology</i> , 2020, 11, 592328.	2.2	3
322	Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 1455.	5.8	96
323	PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity. <i>PLoS Pathogens</i> , 2021, 17, e1009349.	2.1	15
324	Decreased Peripheral Naïve T Cell Number and Its Role in Predicting Cardiovascular and Infection Events in Hemodialysis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 644627.	2.2	10
325	KDM6B-dependent chromatin remodeling underpins effective virus-specific CD8+ T cell differentiation. <i>Cell Reports</i> , 2021, 34, 108839.	2.9	20
326	Runx proteins and transcriptional mechanisms that govern memory CD8 T cell development. <i>Immunological Reviews</i> , 2021, 300, 100-124.	2.8	13
327	Memory T-Cell Heterogeneity and Terminology. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037929.	2.3	26
328	Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C. <i>Cells</i> , 2021, 10, 538.	1.8	4
329	Inspired Epigenetic Modulation Synergy with Adenosine Inhibition Elicits Pyroptosis and Potentiates Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100007.	7.8	39

#	ARTICLE	IF	CITATIONS
330	CharPlant: A De Novo Open Chromatin Region Prediction Tool for Plant Genomes. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 860-871.	3.0	4
331	CD8+ T Cell Responses during HCV Infection and HCC. <i>Journal of Clinical Medicine</i> , 2021, 10, 991.	1.0	22
332	InÂvivo CD8+ TÂcell CRISPR screening reveals control by Fli1 in infection and cancer. <i>Cell</i> , 2021, 184, 1262-1280.e22.	13.5	107
333	Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. <i>Frontiers in Immunology</i> , 2021, 12, 652160.	2.2	12
334	CD8⁺T-Cell Memory: The Why, the When, and the How. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a038661.	2.3	7
335	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. <i>Haematologica</i> , 2021, 106, 1234-1243.	1.7	18
336	The architectural design of CD8+ T cell responses in acute and chronic infection: Parallel structures with divergent fates. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	41
337	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
338	CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1440.	1.7	88
339	Groupâ€2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2â€Neutrophilâ€Induced Immunosuppression. <i>Hepatology</i> , 2021, 74, 2526-2543.	3.6	53
340	E2A-regulated epigenetic landscape promotes memory CD8 T cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	21
341	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. <i>Blood Reviews</i> , 2021, 50, 100832.	2.8	5
342	UTX promotes CD8+ TÂcell-mediated antiviral defenses but reduces TÂcell durability. <i>Cell Reports</i> , 2021, 35, 108966.	2.9	9
344	Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 1819.	1.7	16
345	Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> , 2021, 372, .	6.0	297
346	Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1922.	1.7	29
347	Cellular networks controlling T cell persistence in adoptive cell therapy. <i>Nature Reviews Immunology</i> , 2021, 21, 769-784.	10.6	83
348	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84

#	ARTICLE	IF	CITATIONS
349	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 347-363.	1.5	25
350	Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation. <i>Cell Reports</i> , 2021, 35, 109101.	2.9	20
351	Immune Regulation in Time and Space: The Role of Local- and Long-Range Genomic Interactions in Regulating Immune Responses. <i>Frontiers in Immunology</i> , 2021, 12, 662565.	2.2	13
352	Heads or tails: histone tail clipping regulates macrophage activity. <i>Nature Immunology</i> , 2021, 22, 678-680.	7.0	6
353	“Go, No Go, or Where to Go” does microbiota dictate T cell exhaustion, programming, and HIV persistence?. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 215-222.	1.5	9
354	An exhausted phenotype of T H 2 cells is primed by allergen exposure, but not reinforced by allergen-specific immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2827-2839.	2.7	16
355	Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance. <i>Nature Communications</i> , 2021, 12, 2782.	5.8	20
356	Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 647688.	2.2	19
357	Reversing Post-Infectious Epigenetic-Mediated Immune Suppression. <i>Frontiers in Immunology</i> , 2021, 12, 688132.	2.2	21
358	Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1365-1378.	5.7	38
359	Transcriptional Control of Cell Fate Determination in Antigen-Experienced CD8 T Cells. <i>Cold Spring Harbor Perspectives in Biology</i> , 2022, 14, a037945.	2.3	4
360	Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study. <i>Frontiers in Immunology</i> , 2021, 12, 662441.	2.2	8
361	Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. <i>Nature Immunology</i> , 2021, 22, 809-819.	7.0	113
362	Epigenetic Regulation of Cancer Immune Cells. <i>Seminars in Cancer Biology</i> , 2021, , .	4.3	9
363	Defining the Molecular Hallmarks of T-Cell Memory. <i>Cold Spring Harbor Perspectives in Biology</i> , 2022, 14, a037804.	2.3	2
364	CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?. <i>Clinical Cancer Research</i> , 2021, 27, 5742-5752.	3.2	98
365	Follicular helper-T cells restore CD8 ⁺ -dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. , 2021, 9, e002157.		63
366	A unified atlas of CD8 T cell dysfunctional states in cancer and infection. <i>Molecular Cell</i> , 2021, 81, 2477-2493.e10.	4.5	57

#	ARTICLE	IF	CITATIONS
367	Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal. <i>Cancer Immunology Research</i> , 2021, 9, 939-951.	1.6	35
368	T-cell Exhaustion in Organ Transplantation. <i>Transplantation</i> , 2022, 106, 489-499.	0.5	14
369	CD8+ T Cell Exhaustion in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 715234.	2.2	163
370	PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8 ⁺ T cell exhaustion during metastasis. <i>Cancer Science</i> , 2021, 112, 3437-3454.	1.7	33
371	Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. <i>Nature Immunology</i> , 2021, 22, 1020-1029.	7.0	124
372	Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	36
373	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
374	Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. <i>Nature Immunology</i> , 2021, 22, 1008-1019.	7.0	116
375	COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7481.	1.8	37
376	Improving T cell therapy: in vivo CRISPR-Cas9 screens tell us how to do. <i>Precision Clinical Medicine</i> , 2021, 4, 176-178.	1.3	1
377	Establishment, maintenance, and recall of inflammatory memory. <i>Cell Stem Cell</i> , 2021, 28, 1758-1774.e8.	5.2	98
378	Gene Regulatory Network of Human GM-CSF-Secreting T Helper Cells. <i>Journal of Immunology Research</i> , 2021, 2021, 1-24.	0.9	2
380	Getting better mileage with logically primed CARs. <i>Med</i> , 2021, 2, 785-787.	2.2	2
381	The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. <i>British Journal of Cancer</i> , 2021, 125, 1341-1349.	2.9	21
382	BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection. <i>Nature Immunology</i> , 2021, 22, 996-1007.	7.0	78
383	Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer. <i>Cancers</i> , 2021, 13, 4263.	1.7	32
385	Activation or exhaustion of CD8+ T cells in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2325-2333.	4.8	106
386	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	45

#	ARTICLE	IF	CITATIONS
387	Schröderdingers T Cells: Molecular Insights Into Stemness and Exhaustion. <i>Frontiers in Immunology</i> , 2021, 12, 725618.	2.2	22
388	The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors. <i>BMC Cancer</i> , 2021, 21, 969.	1.1	13
389	A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
390	Epigenetic networks driving T cell identity and plasticity during immunosenescence. <i>Trends in Genetics</i> , 2021, , .	2.9	1
391	Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. <i>Cells</i> , 2021, 10, 2563.	1.8	12
392	An Updated Model for the Epigenetic Regulation of Effector and Memory CD8+ T Cell Differentiation. <i>Journal of Immunology</i> , 2021, 207, 1497-1505.	0.4	5
394	Single-cell technologies to dissect heterogenous immune cell therapy products. <i>Current Opinion in Biomedical Engineering</i> , 2021, 20, 100343.	1.8	1
395	Mapping genomic and epigenomic evolution in cancer ecosystems. <i>Science</i> , 2021, 373, 1474-1479.	6.0	38
396	Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. <i>Pharmacological Research</i> , 2021, 171, 105780.	3.1	196
398	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. <i>Immunity</i> , 2021, 54, 2338-2353.e6.	6.6	111
399	Yangyin Fuzheng Jiedu Prescription exerts anti-tumor immunity in hepatocellular carcinoma by alleviating exhausted T cells. <i>Phytomedicine</i> , 2021, 91, 153722.	2.3	5
400	Epigenetic programming of the immune responses in cancer. , 2022, , 197-235.		1
401	Synthetic receptors for logic gated T cell recognition and function. <i>Current Opinion in Immunology</i> , 2022, 74, 9-17.	2.4	7
402	Chromatin accessibility profiling methods. <i>Nature Reviews Methods Primers</i> , 2021, 1, .	11.8	95
403	Remodeling the chromatin landscape in T lymphocytes by a division of labor among transcription factors. <i>Immunological Reviews</i> , 2021, 300, 167-180.	2.8	7
404	Epigenetic Regulation in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 103-119.	0.8	3
405	Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. <i>Nature Communications</i> , 2021, 12, 409.	5.8	109
406	Hirsutella Sinensis Fungus Regulates CD8+ T Cell Exhaustion Through Involvement of T-Bet/Eomes in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2020, 11, 612620.	1.6	8

#	ARTICLE	IF	CITATIONS
407	A Human In Vitro T Cell Exhaustion Model for Assessing Immuno-Oncology Therapies. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 89-101.	0.1	15
408	Histone Modifications as Biomarkers for Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, 2055, 213-228.	0.4	8
409	The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3059-3082.	1.3	61
410	Landscape and Dynamics of the Transcriptional Regulatory Network During Natural Killer Cell Differentiation. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 501-515.	3.0	16
411	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. <i>Immunity</i> , 2020, 52, 825-841.e8.	6.6	497
412	Chromatin dependencies in cancer and inflammation. <i>Nature Reviews Molecular Cell Biology</i> , 2018, 19, 245-261.	16.1	64
413	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. <i>Nature Communications</i> , 2020, 11, 604.	5.8	44
422	Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. <i>JCI Insight</i> , 2019, 4, .	2.3	148
423	β-catenin and PI3K inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. <i>JCI Insight</i> , 2017, 2, .	2.3	35
424	CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. <i>JCI Insight</i> , 2018, 3, .	2.3	67
425	CD19 CAR T cell product and disease attributes predict leukemia remission durability. <i>Journal of Clinical Investigation</i> , 2019, 129, 2123-2132.	3.9	244
426	Chronic stimulation drives human NK cell dysfunction and epigenetic reprogramming. <i>Journal of Clinical Investigation</i> , 2019, 129, 3770-3785.	3.9	125
427	DNA hypermethylation during tuberculosis dampens host immune responsiveness. <i>Journal of Clinical Investigation</i> , 2020, 130, 3113-3123.	3.9	47
428	Stability and flexibility in chromatin structure and transcription underlies memory CD8 T-cell differentiation. <i>F1000Research</i> , 2019, 8, 1278.	0.8	14
429	Epigenetic changes in fibroblasts drive cancer metabolism and differentiation. <i>Endocrine-Related Cancer</i> , 2019, 26, R673-R688.	1.6	34
430	Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. <i>Oncotarget</i> , 2017, 8, 60257-60269.	0.8	12
431	Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. <i>Oncotarget</i> , 2018, 9, 19065-19078.	0.8	37
432	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3

#	ARTICLE	IF	CITATIONS
433	Exhausted T cells and epigenetic status. <i>Cancer Biology and Medicine</i> , 2020, 17, 923-936.	1.4	32
434	Unlocking the epigenetic code of T cell exhaustion. <i>Translational Cancer Research</i> , 2017, 6, S384-S387.	0.4	12
435	Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries. <i>Viruses</i> , 2019, 11, 106.	1.5	16
436	Re-defining T-Cell Exhaustion: Subset, Function, and Regulation. <i>Immune Network</i> , 2020, 20, e2.	1.6	33
437	Why natural killer cells in triple negative breast cancer?. <i>World Journal of Clinical Oncology</i> , 2020, 11, 464-476.	0.9	33
438	Antigen receptor control of methionine metabolism in T cells. <i>ELife</i> , 2019, 8, .	2.8	132
439	Cancer systems immunology. <i>ELife</i> , 2020, 9, .	2.8	14
440	Chronic LCMV Infection Is Fortified with Versatile Tactics to Suppress Host T Cell Immunity and Establish Viral Persistence. <i>Viruses</i> , 2021, 13, 1951.	1.5	3
441	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. <i>Cancer Cell</i> , 2021, 39, 1578-1593.e8.	7.7	275
443	Archetypes of checkpoint-responsive immunity. <i>Trends in Immunology</i> , 2021, 42, 960-974.	2.9	5
444	T cell responses during HBV and HCV infections: similar but not quite the same?. <i>Current Opinion in Virology</i> , 2021, 51, 80-86.	2.6	10
446	Novel Methods to Overcome Acquired Resistance to Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 97-129.	0.1	0
451	DNA Methylation in T-Cell Development and Differentiation. <i>Critical Reviews in Immunology</i> , 2020, 40, 135-156.	1.0	25
454	Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited. <i>Cancer Immunology Research</i> , 2021, 9, 1373-1382.	1.6	33
455	mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional $\text{I}\hat{\text{a}}\hat{\text{2}}$ and $\text{I}\hat{\text{3}}\hat{\text{1}}$ T cells in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 121-137.	3.0	22
456	Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 127-141.	0.8	0
457	The therapeutic potential of epigenetic manipulation during infectious diseases. , 2020, , 217-236.		1
459	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1333-1353.	1.1	9

#	ARTICLE	IF	CITATIONS
463	Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 147-156.	0.6	0
465	Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. <i>Cell Reports</i> , 2021, 37, 109992.	2.9	37
466	Targeting BMI-1 in B cells restores effective humoral immune responses and controls chronic viral infection. <i>Nature Immunology</i> , 2022, 23, 86-98.	7.0	17
467	T cell-derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death. <i>JCI Insight</i> , 2021, 6, .	2.3	7
468	Cancer immunotherapy: Challenges and limitations. <i>Pathology Research and Practice</i> , 2022, 229, 153723.	1.0	53
469	Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 751590.	1.8	10
470	LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. <i>Nature Communications</i> , 2021, 12, 6831.	5.8	46
471	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 777073.	2.2	5
472	Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. <i>Science Translational Medicine</i> , 2021, 13, eabh0272.	5.8	123
473	Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. <i>Blood</i> , 2022, 139, 2156-2172.	0.6	33
474	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. <i>Cancer Drug Discovery and Development</i> , 2022, , 207-219.	0.2	1
475	Perspective on the Immunotherapy of Pancreatic Cancer. , 2021, , 257-270.		0
476	Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 546.	1.7	5
477	JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. <i>Med</i> , 2022, 3, 42-57.e5.	2.2	11
478	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis Pathways. <i>Advanced Science</i> , 2022, 9, e2103508.	5.6	21
479	G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. , 2022, 10, e003543.		10
480	Resistance and recurrence of malignancies after CAR-T cell therapy. <i>Experimental Cell Research</i> , 2022, 410, 112971.	1.2	4
481	Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells. <i>Cancers</i> , 2022, 14, 323.	1.7	6

#	ARTICLE	IF	CITATIONS
482	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
483	Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 796477.	1.3	0
484	Reduced chromatin accessibility to CD4 T cell super-enhancers encompassing susceptibility loci of rheumatoid arthritis. <i>EBioMedicine</i> , 2022, 76, 103825.	2.7	1
485	Gene Regulatory Circuits in Innate and Adaptive Immune Cells. <i>Annual Review of Immunology</i> , 2022, 40, 387-411.	9.5	6
486	ERCC6L is a biomarker and therapeutic target for nonâ€“small cell lung adenocarcinoma. <i>Medical Oncology</i> , 2022, 39, 51.	1.2	4
487	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 ^{int} TCF-1 ⁺ CD8 ⁺ T ^{â€“} cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
488	Epigenetic regulation of natural killer cell memory*. <i>Immunological Reviews</i> , 2022, 305, 90-110.	2.8	17
489	Epigenetics and CD8 ⁺ T cell memory*. <i>Immunological Reviews</i> , 2022, 305, 77-89.	2.8	22
490	Pan-cancer single-cell landscape of tumor-infiltrating T cells. <i>Science</i> , 2021, 374, abe6474.	6.0	460
491	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
492	New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy. <i>Cells</i> , 2022, 11, 708.	1.8	8
494	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. <i>Science</i> , 2022, 375, 877-884.	6.0	156
495	Knowns and Unknowns about CAR-T Cell Dysfunction. <i>Cancers</i> , 2022, 14, 1078.	1.7	23
496	Batf-mediated epigenetic control of effector CD8 ⁺ T cell differentiation. <i>Science Immunology</i> , 2022, 7, eabi4919.	5.6	19
497	Fatty Acid Metabolism and Cancer Immunotherapy. <i>Current Oncology Reports</i> , 2022, 24, 659-670.	1.8	23
498	CD8 ⁺ T-Cell Exhaustion Phenotype in Chronic Hepatitis C Virus Infection Is Associated With Epitope Sequence Variation. <i>Frontiers in Immunology</i> , 2022, 13, 832206.	2.2	4
499	Human epigenetic and transcriptional T ^{â€“} cell differentiation atlas for identifying functional T ^{â€“} cell-specific enhancers. <i>Immunity</i> , 2022, 55, 557-574.e7.	6.6	47
502	PeakVI: A deep generative model for single-cell chromatin accessibility analysis. <i>Cell Reports Methods</i> , 2022, 2, 100182.	1.4	34

#	ARTICLE	IF	CITATIONS
503	Increased DNA methylation, cellular senescence and premature epigenetic aging in guinea pigs and humans with tuberculosis. <i>Aging</i> , 2022, 14, 2174-2193.	1.4	15
504	Protein arginine N-methyltransferase 4 (PRMT4) contributes to lymphopenia in experimental sepsis. <i>Thorax</i> , 2023, 78, 383-393.	2.7	5
505	T cell senescence and impaired CMV-specific response are associated with infection risk in kidney transplant recipients. <i>Human Immunology</i> , 2022, 83, 273-280.	1.2	7
506	TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. , 2022, 10, e004711.		69
507	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
508	Expression of Id3 represses exhaustion of anti-tumor CD8 T cells in liver cancer. <i>Molecular Immunology</i> , 2022, 144, 117-126.	1.0	5
510	NFAT-dependent and -independent exhaustion circuits program maternal CD8 T cell hypofunction in pregnancy. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	13
511	Vascular Microenvironment, Tumor Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 811485.	2.2	43
512	DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon- γ Signature, Signatures of Immune Infiltrates, and Survival. <i>Journal of Immunotherapy</i> , 2022, 45, 194-206.	1.2	6
513	HDAC Inhibition to Prime Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 66.	1.7	32
514	DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. <i>Clinical Epigenetics</i> , 2022, 14, 50.	1.8	9
529	MicroRNA-29a attenuates CD8 T cell exhaustion and induces memory-like CD8 T cells during chronic infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2106083119.	3.3	7
530	A variety of "exhausted" T cells in the tumor microenvironment. <i>International Immunology</i> , 2022, 34, 563-570.	1.8	13
531	Dissecting the heterogeneity of exhausted T cells at the molecular level. <i>International Immunology</i> , 2022, 34, 547-553.	1.8	2
532	A Unique Epigenomic Landscape Defines CD8 Tissue-Resident Memory T Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
533	The TOX subfamily: all-round players in the immune system. <i>Clinical and Experimental Immunology</i> , 2022, 208, 268-280.	1.1	4
534	T cell receptor and IL-2 signaling strength control memory CD8+ T cell functional fitness via chromatin remodeling. <i>Nature Communications</i> , 2022, 13, 2240.	5.8	17
535	Spatial determinants of CD8+ T cell differentiation in cancer. <i>Trends in Cancer</i> , 2022, 8, 642-654.	3.8	8

#	ARTICLE	IF	CITATIONS
537	CD4 ⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022.		7
538	Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer. Theranostics, 2022, 12, 3818-3833.	4.6	40
540	Epigenetic regulation of T cell exhaustion. Nature Immunology, 2022, 23, 848-860.	7.0	82
541	Stem-like precursors are the fount to sustain persistent CD8+ T cell responses. Nature Immunology, 2022, 23, 836-847.	7.0	50
542	HIV UTR, LTR, and Epigenetic Immunity. Viruses, 2022, 14, 1084.	1.5	6
543	Pan-Cancer Methylated Dysregulation of Long Non-coding RNAs Reveals Epigenetic Biomarkers. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	3
544	Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells. Frontiers in Immunology, 0, 13, .	2.2	1
545	Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4+ T Cells. Frontiers in Immunology, 0, 13, .	2.2	6
546	Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell, 2022, 40, 768-786.e7.	7.7	104
547	CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas. Nature Communications, 2022, 13, .	5.8	11
548	Application of ATAC-seq in tumor-specific T cell exhaustion. Cancer Gene Therapy, 2023, 30, 1-10.	2.2	4
551	CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma. Journal of Immunotherapy, 2022, 45, 324-334.	1.2	8
552	Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction. Leukemia, 2022, 36, 2656-2668.	3.3	15
553	Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. Science Immunology, 2022, 7, .	5.6	35
554	Methionine cycle-dependent regulation of T cells in cancer immunity. Frontiers in Oncology, 0, 12, .	1.3	5
555	New Immuno-oncology Targets and Resistance Mechanisms. Current Treatment Options in Oncology, 2022, 23, 1201-1218.	1.3	10
556	Epigenetic engineering for optimal CAR-T cell therapy. Cancer Science, 0, , .	1.7	4
557	Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function. EBioMedicine, 2022, 84, 104254.	2.7	4

#	ARTICLE	IF	CITATIONS
558	CD137 (4-1BB) Signaling Drives a TcR-Independent Exhaustion Program in CD8 T Cells. SSRN Electronic Journal, 0, , .	0.4	0
559	Metabolic plasticity and regulation of T cell exhaustion. Immunology, 2022, 167, 482-494.	2.0	14
560	Introduction: Redefining T-cell Exhaustion Special Issue. International Immunology, 2022, 34, 545-546.	1.8	0
561	PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature, 2022, 610, 173-181.	13.7	96
562	Loss of CD47 alters CD8+ T cell activation <i>in vitro</i> and immunodynamics in mice. OncoImmunology, 2022, 11, .	2.1	10
563	Epigenetics: An opportunity to shape innate and adaptive immune responses. Immunology, 2022, 167, 451-470.	2.0	9
564	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 9985.	1.8	11
566	TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer. Cancers, 2022, 14, 4594.	1.7	0
567	CD8 ⁺ T cell exhaustion in anti-tumour immunity: The new insights for cancer immunotherapy. Immunology, 2023, 168, 30-48.	2.0	20
569	Divergent clonal differentiation trajectories of T cell exhaustion. Nature Immunology, 2022, 23, 1614-1627.	7.0	49
571	Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. Journal of Zhejiang University: Science B, 2022, 23, 793-811.	1.3	9
572	Clinical implications of T cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology, 2022, 19, 775-790.	12.5	182
573	Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics. Nature Immunology, 2022, 23, 1600-1613.	7.0	62
574	Non-viral precision T cell receptor replacement for personalized cell therapy. Nature, 2023, 615, 687-696.	13.7	85
575	Role of CXCR5+ CD8+ T cells in human immunodeficiency virus-1 infection. Frontiers in Microbiology, 0, 13, .	1.5	2
576	Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. Biomedicines, 2022, 10, 2809.	1.4	8
577	BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine, 2022, 14, .	5.8	25
578	Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. Clinical Immunology, 2022, 245, 109177.	1.4	12

#	ARTICLE	IF	CITATIONS
580	Estimation of Tumor Immune Signatures from Transcriptomics Data. Springer Handbooks of Computational Statistics, 2022, , 311-338.	0.2	0
581	Strategies to enhance CAR-T persistence. Biomarker Research, 2022, 10, .	2.8	15
582	Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. Immuno, 2022, 2, 671-691.	0.6	2
583	Multiplexed engineering and precision gene editing in cellular immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	4
584	Identification of human progenitors of exhausted CD8+ T cells associated with elevated IFN- γ response in early phase of viral infection. Nature Communications, 2022, 13, .	5.8	8
585	CD8+ T cell exhaustion and cancer immunotherapy. Cancer Letters, 2023, 559, 216043.	3.2	18
586	Expression of Inhibitory Receptors TIGIT, TIM-3, and LAG-3 on CD4+ T Cells from Patients with Different Clinical Forms of Chronic Chagas Disease. Journal of Immunology, 2023, 210, 568-579.	0.4	2
587	Epigenetics in T-cell driven inflammation and cancer. Seminars in Cell and Developmental Biology, 2024, 154, 250-260.	2.3	2
588	Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
590	Intimate communications within the tumor microenvironment: stromal factors function as an orchestra. Journal of Biomedical Science, 2023, 30, .	2.6	15
591	The scientific basis of combination therapy for chronic hepatitis B functional cure. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 238-253.	8.2	26
592	Integrated single-cell profiling dissects cell-state-specific enhancer landscapes of human tumor-infiltrating CD8+ T cells. Molecular Cell, 2023, 83, 622-636.e10.	4.5	7
594	T-Cell Exhaustion in Cancers. , 2023, , 1-29.		0
595	Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versus chronic infection. PLoS Biology, 2023, 21, e3001983.	2.6	8
596	Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. Journal of Biomedical Science, 2023, 30, .	2.6	7
597	T cell exhaustion in malignant gliomas. Trends in Cancer, 2023, 9, 270-292.	3.8	23
598	MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma. Frontiers in Oncology, 0, 13, .	1.3	0
601	Regulation and Immunotherapeutic Targeting of the Epigenome in Exhausted CD8 T Cell Responses. Journal of Immunology, 2023, 210, 869-879.	0.4	2

#	ARTICLE	IF	CITATIONS
602	Immunological scars after cure of hepatitis C virus infection: Long-term HepC?. Current Opinion in Immunology, 2023, 82, 102324.	2.4	1
603	Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities. Frontiers in Immunology, 0, 14, .	2.2	1
604	Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics. Antioxidants, 2023, 12, 444.	2.2	9
605	Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma. Frontiers in Immunology, 0, 14, .	2.2	2
606	TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer. Aging, 0, , .	1.4	0
608	Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma. Frontiers in Immunology, 0, 14, .	2.2	1
609	De-novo reconstruction and identification of transcriptional gene regulatory network modules differentiating single-cell clusters. NAR Genomics and Bioinformatics, 2023, 5, .	1.5	0
611	Immunogen-Specific Strengths and Limitations of the Activation-Induced Marker Assay for Assessing Murine Antigen-Specific CD4+ T Cell Responses. Journal of Immunology, 2023, 210, 916-925.	0.4	0
612	Role of regulation of PD-1 and PD-L1 expression in sepsis. Frontiers in Immunology, 0, 14, .	2.2	6
613	Exhausted CD8+ T cells face a developmental fork in the road. Trends in Immunology, 2023, 44, 276-286.	2.9	5
614	A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2023, 29, 2052-2065.	3.2	8
615	Combination immunotherapy for hepatocellular carcinoma. Journal of Hepatology, 2023, 79, 506-515.	1.8	46
616	Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	4
618	Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. Molecular Cell, 2023, 83, 1216-1236.e12.	4.5	13
619	Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming. Cancers, 2023, 15, 1935.	1.7	2
620	Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	10
621	Regulatory Mechanisms and Reversal of CD8+T Cell Exhaustion: A Literature Review. Biology, 2023, 12, 541.	1.3	2
622	T-cell heterogeneity, progenitor-progeny relationships, and function during latent and chronic viral infections. Immunological Reviews, 2023, 316, 136-159.	2.8	3

#	ARTICLE	IF	CITATIONS
623	Cell-Intrinsic CD38 Expression Sustains Exhausted CD8 ⁺ T Cells by Regulating Their Survival and Metabolism during Chronic Viral Infection. <i>Journal of Virology</i> , 2023, 97, .	1.5	6
629	Challenges for single-cell epigenetic analysis. , 2023, , 553-576.		0
631	Localization, tissue biology and T cell state “ implications for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2023, 23, 807-823.	10.6	10
645	New insights into T-cell exhaustion in liver cancer: from mechanism to therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 12543-12560.	1.2	1
647	Cancer Vaccines. , 2023, , 191-210.e9.		0
654	The road not taken en route to T cell exhaustion. <i>Nature Immunology</i> , 2023, 24, 1402-1404.	7.0	0
655	Regulation of CD8+ T memory and exhaustion by the mTOR signals. , 2023, 20, 1023-1039.		4
662	Stem-like exhausted and memory CD8+ T cells in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 780-798.	12.8	5
683	Fatty acid metabolism of immune cells: a new target of tumour immunotherapy. <i>Cell Death Discovery</i> , 2024, 10, .	2.0	1